augmentin fruit 80 / 11.4 mg/ml jauhe oraalisuspensiota varten
glaxosmithkline (ireland) limited - amoxicillinum trihydricum,kalii clavulanas - jauhe oraalisuspensiota varten - 80 / 11.4 mg/ml - amoksisilliini ja beetalaktamaasin estäjä
suiseng coli / c injektioneste, suspensio
laboratorios hipra s.a. - f5 fimbrial adhesin of e. coli, clostridium perfringens type c beta1 toxoid, f4ab fimbrial adhesin of e. coli, f4ac fimbrial adhesin of e. coli, f6 fimbrial adhesin of e. coli, clostridium novyi type b toxoid, lt enterotoxoid of e.coli - injektioneste, suspensio
spectrabactin vet 400 mg / 100 mg tabletti
dechra regulatory b.v. - amoxicillin trihydrate, potassium clavulanate - tabletti - 400 mg / 100 mg - amoksisilliini ja entsyymi-inhibiittori
spectrabactin vet 40 mg / 10 mg tabletti
dechra regulatory b.v. - amoxicillin trihydrate, potassium clavulanate - tabletti - 40 mg / 10 mg - amoksisilliini ja entsyymi-inhibiittori
spectrabactin vet 200 mg / 50 mg tabletti
dechra regulatory b.v. - amoxicillin trihydrate, potassium clavulanate - tabletti - 200 mg / 50 mg - amoksisilliini ja entsyymi-inhibiittori
enrocat vet 25 mg/ml oraalisuspensio
livisto int'l, s.l. - enrofloxacin - oraalisuspensio - 25 mg/ml - enrofloksasiini
clavaseptin 600 mg / 150 mg tabletti
vetoquinol s.a. - potassium clavulanate, amoxicillin trihydrate - tabletti - 600 mg / 150 mg - amoksisilliini ja entsyymi-inhibiittori
inaqovi
otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemia, myeloidi - antineoplastiset aineet - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multiple myeloma - antineoplastiset aineet - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemia, myeloidi - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.